Red blood cell alloimmunization prevalence and hemolytic disease of the fetus and newborn in Israel: A retrospective study

• Published in: Transfusion (Philadelphia, Pa.) Vol. 60; no. 11; pp. 2684 - 2690
• Main Authors: Rahimi‐Levene, Naomi, Chezar, Judith, Yahalom, Vered
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01-11-2020; Wiley Subscription Services, Inc
• Subjects: ABO system; Alloantibodies; Anemia; Antibodies; Erythrocytes; Fetuses; Hemolytic disease; Isoimmunization; Morbidity; Neonates; Pregnancy; Transfusion
• ISSN: 0041-1132; 1537-2995
• DOI: 10.1111/trf.15987

Background
Hemolytic disease of the fetus and newborn (HDFN) is a severe form of anemia caused by maternal antibodies against fetal red blood cells (RBC) that can cause intrauterine and perinatal morbidity and mortality. The prevalence and specificities of alloantibodies among Israeli pregnant women and clinical outcomes for their fetuses and newborns are unknown.
Study Design and Methods
A retrospective study of women who gave birth between January 1, 2011, and December 31, 2011, was performed. Data were obtained for obstetric admissions from 16 of 27 hospitals, which included results of maternal ABO, D, antibody screens, antibody identification, and requirements for intrauterine or newborn exchange transfusions.
Results
Data on 90 948 women representing 70% of all births during 2011 were analyzed. Antibody screen was positive in 5245 (5.8%) women. Alloantibodies, excluding anti‐D titer (<16) were identified in 900 (1.0%) women. Of 191 D– women, 75 (39.3%) had anti‐D titer of 16 or greater. Other common clinically significant antibodies were anti‐E (204, 23%), anti‐K (145, 16%), and anti‐c (97, 10.8%) alone or in antibody combinations. Multiple alloantibodies were observed in 132 of 900 (15%) of women. Severe HDFN developed in 6.8% (9/132) of these pregnancies. Seventeen fetuses and newborns (0.02% of births) including one set of twins required RBC transfusions. Two fetuses whose mothers had multiple alloantibodies received intrauterine transfusions; one of them was hydropic and died.
Conclusion
The prevalence of RBC alloantibodies was 1.0% among Israeli pregnant women. Transfusion was required in 0.02% of the fetuses and newborns. Severe HDFN developed in 6.8% of pregnancies with multiple maternal alloantibodies.